Darolutamide Patent Expiration

Darolutamide is Used for treating non-metastatic castration-resistant prostate cancer. It was first introduced by Bayer Healthcare Pharmaceuticals Inc in its drug Nubeqa on Jul 30, 2019.


Darolutamide Patents

Given below is the list of patents protecting Darolutamide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Nubeqa US11168058 Manufacture of a crystalline pharmaceutical product Feb 27, 2038 Bayer Healthcare
Nubeqa US10010530 Carboxamide derivative and its diastereomers in stable crystalline form Jan 28, 2036 Bayer Healthcare
Nubeqa US10383853 Carboxamide derivative and its diastereomers in stable crystalline form Jan 28, 2036 Bayer Healthcare
Nubeqa US10835515 Carboxamide derivative and its diastereomers in stable crystalline form Jan 28, 2036 Bayer Healthcare
Nubeqa US8975254 Androgen receptor modulating compounds Mar 25, 2033 Bayer Healthcare
Nubeqa US10711013 Androgen receptor modulating compounds Oct 27, 2030 Bayer Healthcare
Nubeqa US11046713 Androgen receptor modulating compounds Oct 27, 2030 Bayer Healthcare
Nubeqa US9657003 Androgen receptor modulating compounds Oct 27, 2030 Bayer Healthcare



Darolutamide's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Darolutamide News

Orion, a pharmaceutical company from Finland, looks to increase sales in the United States by promoting its successful prostate cancer medication.

26 Sep, 2024

Bayer, in collaboration with Orion, applies to U.S. FDA for third indication of ...

26 Sep, 2024

Bayer's Nubeqa, a Drug for Prostate Cancer, Expected to Achieve Significant Sales in 2024.

22 Mar, 2024

See More